• Chosa Oncology signed an agreement with a CLIA-certified laboratory to develop and validate Platin-DRP for US commercialization.
• First revenue is expected in summer 2027, subject to successful analytical validation and implementation under the laboratory's CLIA certification.
• Expected first-year sales total 300-500 tests, against an estimated US market potential exceeding 250,000 tests annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 202611040435BITN____UKPR__EN_20261104-BIT-4609-0) on November 04, 2026, and is solely responsible for the information contained therein.